版本:
中国

BRIEF-Capricor Therapeutics plans to discuss with U.S. FDA potential product registration strategies for CAP-1002

May 31 Capricor Therapeutics Inc:

* Capricor Therapeutics - co plans to discuss with U.S. FDA potential product registration strategies for cap-1002 in duchenne muscular dystrophy indication

* Formal meeting between Capricor & FDA is scheduled to be held by telephone in second half of June 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐